There is provided a use of a modified double-stranded RNA (dsRNA) or modifiedsmall interfering RNA (siRNA) for inhibiting Hepatitis C Virus (HCV)replication in apatient. The modified dsRNA or modified siRNA comprises a first strand and asecond strand,wherein the first and second strand are each no more than about 30ribonucleotides in lengthand wherein the first or second strand targets HCV. The modified dsRNA ormodified siRNAis cholesterol-labeled. The modified dsRNA or modified siRNA is formulated foradministration to said patient simultaneously or in any order with acholesterol-lowering drugthat functions to reduce the level of competing cholesterol in the serum,allowing moreefficient uptake of the cholesterol-labeled modified dsRNA or modified siRNAbyhepatocytes.
